Prothena (NASDAQ:PRTA - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($1.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.20), Zacks reports. The business had revenue of $2.83 million during the quarter, compared to analyst estimates of $8.18 million. Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The firm's quarterly revenue was up 5500.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.34) earnings per share.
Prothena Price Performance
Shares of PRTA traded down $0.02 during trading hours on Tuesday, hitting $7.59. The stock had a trading volume of 2,205,168 shares, compared to its average volume of 575,009. Prothena has a 1-year low of $6.92 and a 1-year high of $25.42. The firm has a 50 day simple moving average of $10.95 and a 200-day simple moving average of $13.51. The firm has a market capitalization of $408.55 million, a P/E ratio of -3.30 and a beta of 0.11.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on PRTA shares. HC Wainwright lowered their price target on Prothena from $48.00 to $30.00 and set a "buy" rating for the company in a report on Friday. StockNews.com raised Prothena from a "sell" rating to a "hold" rating in a research note on Monday, February 24th. Oppenheimer boosted their target price on Prothena from $58.00 to $62.00 and gave the stock an "outperform" rating in a research note on Friday, February 7th. Chardan Capital reiterated a "buy" rating and set a $40.00 price objective on shares of Prothena in a research report on Friday. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Prothena in a research report on Friday, February 21st. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Prothena has a consensus rating of "Moderate Buy" and a consensus price target of $51.71.
View Our Latest Analysis on Prothena
Prothena Company Profile
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Read More
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
